poisar

Stocks · News reference

NeOnc shares are trading lower. The company announced topline results from the Phase 2a portion of NEO100-01, an open-label study of intranasal NEO100 in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma.

BenzingaAug 12, 2026, 4:56 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Aug 12, 2026, 4:56 PM
Checked
Aug 12, 2026, 4:56 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading